Matthew J Spindler
Overview
Explore the profile of Matthew J Spindler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mizrahi R, Lin W, Gras A, Niedecken A, Wagner E, Keating S, et al.
Pathogens
. 2022 Jul;
11(7).
PMID: 35890050
Conventionally, hyperimmune globulin drugs manufactured from pooled immunoglobulins from vaccinated or convalescent donors have been used in treating infections where no treatment is available. This is especially important where multi-epitope...
2.
Heather J, Spindler M, Alonso M, Shui Y, Millar D, Johnson D, et al.
Nucleic Acids Res
. 2022 Mar;
50(12):e68.
PMID: 35325179
The study and manipulation of T cell receptors (TCRs) is central to multiple fields across basic and translational immunology research. Produced by V(D)J recombination, TCRs are often only recorded in...
3.
Fenix A, Miyaoka Y, Bertero A, Blue S, Spindler M, Tan K, et al.
Nat Commun
. 2021 Nov;
12(1):6324.
PMID: 34732726
Mutations in the cardiac splicing factor RBM20 lead to malignant dilated cardiomyopathy (DCM). To understand the mechanism of RBM20-associated DCM, we engineered isogenic iPSCs with DCM-associated missense mutations in RBM20...
4.
Keating S, Mizrahi R, Adams M, Asensio M, Benzie E, Carter K, et al.
Nat Biotechnol
. 2021 Apr;
39(8):989-999.
PMID: 33859400
Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin, have multiple drawbacks, including low potency, impurities, insufficient supply and batch-to-batch variation. Here we describe a microfluidics and molecular genomics strategy for...
5.
Spindler M, Nelson A, Wagner E, Oppermans N, Bridgeman J, Heather J, et al.
Nat Biotechnol
. 2020 May;
38(5):609-619.
PMID: 32393905
T cells engineered to express antigen-specific T cell receptors (TCRs) are potent therapies for viral infections and cancer. However, efficient identification of clinical candidate TCRs is complicated by the size...
6.
Medina-Cucurella A, Mizrahi R, Asensio M, Edgar R, Leong J, Leong R, et al.
Antibodies (Basel)
. 2019 Sep;
8(1).
PMID: 31544823
To discover therapeutically relevant antibody candidates, many groups use mouse immunization followed by hybridoma generation or B cell screening. One modern approach is to screen B cells by generating natively...
7.
Asensio M, Lim Y, Wayham N, Stadtmiller K, Edgar R, Leong J, et al.
MAbs
. 2019 Mar;
11(5):870-883.
PMID: 30898066
Immunization of mice followed by hybridoma or B-cell screening is one of the most common antibody discovery methods used to generate therapeutic monoclonal antibody (mAb) candidates. There are a multitude...
8.
Adler A, Bedinger D, Adams M, Asensio M, Edgar R, Leong R, et al.
MAbs
. 2018 Jan;
10(3):431-443.
PMID: 29376776
Deep sequencing and single-chain variable fragment (scFv) yeast display methods are becoming more popular for discovery of therapeutic antibody candidates in mouse B cell repertoires. In this study, we compare...
9.
Adler A, Mizrahi R, Spindler M, Adams M, Asensio M, Edgar R, et al.
MAbs
. 2017 Aug;
9(8):1270-1281.
PMID: 28846506
Conventionally, mouse hybridomas or well-plate screening are used to identify therapeutic monoclonal antibody candidates. In this study, we present an alternative to hybridoma-based discovery that combines microfluidics, yeast single-chain variable...
10.
Adler A, Mizrahi R, Spindler M, Adams M, Asensio M, Edgar R, et al.
MAbs
. 2017 Aug;
9(8):1282-1296.
PMID: 28846502
Affinity-matured, functional anti-pathogen antibodies are present at low frequencies in natural human repertoires. These antibodies are often excellent candidates for therapeutic monoclonal antibodies. However, mining natural human antibody repertoires is...